Prot #CC-90009-AML-001: A Phase 1, Open-Label, Dose-Finding Study Of CC-90009, A Novel Cereblon E3 Ligase Modulating Drug, In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia

Project: Research project

Project Details

StatusActive
Effective start/end date10/18/1610/18/22

Funding

  • ICON Clinical Research, LLC (Prot #CC-90009-AML-001)
  • Celgene Corporation (Prot #CC-90009-AML-001)